中国实用内科杂志2025，Vol.45Issue(2)：105-109,5.DOI:10.19538/j.nk2025020105
聚乙二醇干扰素治疗降低乙型肝炎病毒相关肝细胞癌研究进展
Progress in the study of PEG-IFNα therapy in reducing HBV-related hepatocellular carcinoma
摘要
Abstract
Hepatocellular carcinoma(HCC)remains a malignant tumor that severely affects the health of the people in our country.The most common cause of HCC in our country is infection with the hepatitis B virus(HBV).Although eliminating HBV remains a challenge,antiviral therapy can indeed induce the reversal of liver fibrosis and reduce the incidence of HCC.For patients undergoing antiviral therapy,the risk of liver cancer is reduced by 40％-60％compared to patients who have not received treatment.Currently,anti-HBV drugs aredivided into pegylated interferon(PEG-IFNα)and nucleos(t)ide analogs(NAs).Even under active anti-HBV treatment,the risk of HCC still exists.Existing evidence suggests that PEG-IFNα is superior to NAs in reducing HBV-related HCC,and this article reviews the research progress in PEG-IFNαin reducing HBV-related HCC.关键词
乙型肝炎病毒/聚乙二醇干扰素/肝细胞癌Key words
hepatitis B virus/pegylated interferon alpha/hepatocellular carcinoma分类
医药卫生引用本文复制引用
郑莹莹,曾达武..聚乙二醇干扰素治疗降低乙型肝炎病毒相关肝细胞癌研究进展[J].中国实用内科杂志,2025,45(2):105-109,5.基金项目
福建省肝病与胃肠疾病临床医学研究中心(2023GBYJ-YL-1) （2023GBYJ-YL-1）
